This review focuses on newer medications for the treatment of pain as well as on new
guidelines and indications for the use of established medications. With regard to classical …

Advances in cannabis research have paralleled developments in opioid pharmacology
whereby a psychoactive plant extract has elucidated novel endogenous signalling systems …

Chronic pain is highly prevalent in multiple sclerosis (MS). Pain heterogeneity may
contribute to poor treatment outcomes. The aim of this study was to characterize pain …

Objectives To determine the effects of cannabis, cannabinoids, and their administration
routes on pain and adverse euphoria events. Data sources A systematic search was …

While pain is a common problem in patients with multiple sclerosis (MS), it is not frequently
mentioned by patients and a more direct approach is required in order to obtain information …

Synthetic Cannabinoids (CBs) are a novel class of psychoactive substances that have
rapidly evolved around the world with the addition of diverse structural modifications to …

BACKGROUND: CB1 cannabinoid receptors in the brain are known to participate in the
regulation of reward-based behaviors. However, the contribution of each of the …

The cannabinoid (CB) system is widespread in the central nervous system and is crucial for
controlling a range of neurophysiological processes such as pain, appetite, and cognition …

Objective. The aim of our study was to better investigate the role of Sativex® in improving
pain in multiple sclerosis (MS) patients by means of either clinical or neurophysiological …

Objectives To assess the benefits and harms of cannabinoids in participants with pain.
Design Systematic review of randomised clinical trials with meta-analysis, Trial Sequential …